BridgeBio Oncology Therapeutics, Inc. (BBOT)
NGM – Real Time Price. Currency in USD
7.40
-0.29 (-3.77%)
At close: Jun 26, 2026, 4:00 PM EDT
7.40
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Find any stock by ticker or company name

NGM – Real Time Price. Currency in USD
7.40
-0.29 (-3.77%)
At close: Jun 26, 2026, 4:00 PM EDT
7.40
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $52.7M significantly exceed its total debt $2.6M, ensuring strong financial flexibility
Total current assets $266.5M exceed Total current liabilities $43.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$35.9M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 6.16 | 6.05 | 10 | |
| Quick ratio | 6.16 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | -208K | -610K | -796K |
| Operating Income | -4K | -42K | -81M | -146M | -140M |
| Net Income | -4K | -42K | -74M | -134M | -125M |
| EBITDA | -4K | -42K | -81M | -145M | -139M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 98.88 | 5.5 |
| Next quarter | N/A | 43.79 | 5.5 |
| Current year | N/A | 46.23 | 5.5 |
| Next year | N/A | 4.8 | 2.5 |
| Weighted average score | 4.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -8.52 | -7.36 | 15.05 | 5.3 |
| Y/Y | 999 | -90.9 | 98.99 | -81.87 | 5.5 |
| 3y average | 999 | -59738.84 | N/A | 630.04 | 5.5 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 4.3 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |